Terms: = Uterine cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Clinical Outcome
12 results:
1. The MRI-guided two adaptive brachytherapy fractions versus one adaptive brachytherapy fraction in one application for the cervical cancer: a retrospective study.
Song S; Han D; Zhang N; Mao Z; Guo X; Cheng G
Radiat Oncol; 2023 Mar; 18(1):46. PubMed ID: 36879287
[TBL] [Abstract] [Full Text] [Related]
2. Prohibitin 1 interacts with p53 in the regulation of mitochondrial dynamics and chemoresistance in gynecologic cancers.
Kong B; Han CY; Kim SI; Patten DA; Han Y; Carmona E; Shieh DB; Cheung AC; Mes-Masson AM; Harper ME; Song YS; Tsang BK
J Ovarian Res; 2022 Jun; 15(1):70. PubMed ID: 35668443
[TBL] [Abstract] [Full Text] [Related]
3. Epigenetic silencing of Rab39a promotes epithelial to mesenchymal transition of cervical cancer through akt signaling.
Zou C; Fan J; He M; Xu Y; Wang K; Cai Y; Li M
Exp Cell Res; 2019 May; 378(2):139-148. PubMed ID: 30826396
[TBL] [Abstract] [Full Text] [Related]
4. In-vitro and in-vivo combined effect of ARQ 092, an akt inhibitor, with ARQ 087, a FGFR inhibitor.
Yu Y; Hall T; Eathiraj S; Wick MJ; Schwartz B; Abbadessa G
Anticancer Drugs; 2017 Jun; 28(5):503-513. PubMed ID: 28240679
[TBL] [Abstract] [Full Text] [Related]
5. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
Ayhan A; Kuhn E; Wu RC; Ogawa H; Bahadirli-Talbott A; Mao TL; Sugimura H; Shih IM; Wang TL
Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100
[TBL] [Abstract] [Full Text] [Related]
6. CD24 expression as a marker for predicting clinical outcome and invasive activity in uterine cervical cancer.
Tanaka T; Terai Y; Kogata Y; Ashihara K; Maeda K; Fujiwara S; Yoo S; Tanaka Y; Tsunetoh S; Sasaki H; Kanemura M; Tanabe A; Ohmichi M
Oncol Rep; 2015 Nov; 34(5):2282-8. PubMed ID: 26351781
[TBL] [Abstract] [Full Text] [Related]
7. Dualistic classification of epithelial ovarian cancer: surgical and survival outcomes in a large retrospective series.
Panici PB; Marchetti C; Salerno L; Musella A; Vertechy L; Palaia I; Perniola G; Ruscito I; Boni T; Angioli R; Muzii L
Ann Surg Oncol; 2014 Sep; 21(9):3036-41. PubMed ID: 24770721
[TBL] [Abstract] [Full Text] [Related]
8. Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients.
Liu H; Yang Y; Xiao J; Yang S; Liu Y; Kang W; Li X; Zhang F
Microvasc Res; 2014 May; 93():1-8. PubMed ID: 24603190
[TBL] [Abstract] [Full Text] [Related]
9. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC clinical Trials Group.
Oza AM; Elit L; Tsao MS; Kamel-Reid S; Biagi J; Provencher DM; Gotlieb WH; Hoskins PJ; Ghatage P; Tonkin KS; Mackay HJ; Mazurka J; Sederias J; Ivy P; Dancey JE; Eisenhauer EA
J Clin Oncol; 2011 Aug; 29(24):3278-85. PubMed ID: 21788564
[TBL] [Abstract] [Full Text] [Related]
10. Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment.
Meng X; Brachova P; Yang S; Xiong Z; Zhang Y; Thiel KW; Leslie KK
PLoS One; 2011; 6(6):e20920. PubMed ID: 21687633
[TBL] [Abstract] [Full Text] [Related]
11. PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer.
Urick ME; Rudd ML; Godwin AK; Sgroi D; Merino M; Bell DW
Cancer Res; 2011 Jun; 71(12):4061-7. PubMed ID: 21478295
[TBL] [Abstract] [Full Text] [Related]
12. Combined PTEN and p27kip1 protein expression patterns are associated with obesity and prognosis in endometrial carcinomas.
Dellas A; Jundt G; Sartorius G; Schneider M; Moch H
Clin Cancer Res; 2009 Apr; 15(7):2456-62. PubMed ID: 19293259
[TBL] [Abstract] [Full Text] [Related]
